Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alendronate for Glucocorticoid-Associated Osteopenia and Osteoporosis in Children and Adolescents
NCT00209469Phase 3Unknown
- Sponsor
- Glaser Pediatric Research Network
- Start
- Jul 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteopenia and osteoporosis comparing Alendronate with Standard of Care (2 arms). Primary endpoint: Mean change of individual AP spine bone mineral density at 30 months. Status: unknown.
02
Drugs
alendronate
03
Conditions
osteopeniaosteoporosis
Beyond the preview
Go deeper on NCT00209469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00209469.